Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive Effect of Clopidogrel on Systemic Sclerosis Development in Patients With Specific Dysimmunity and Raynaud Phenomenon
2020-000309-10Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) and Raynaud disease comparing Clopidogrel arm with Placebo arm (2 arms). Primary endpoint: Occurrence of systemic sclerosis at 5 years. Started May 2021; status: active.
02
Drugs
clopidogrel
03
Conditions
systemic sclerosis (SSc)Raynaud disease
Beyond the preview
Go deeper on 2020-000309-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000309-10.